Aurobindo Pharma shares gain after Eugia wins USFDA approval for liver transplant drug
Aurobindo Pharma shares gain after Eugia wins USFDA approval for liver transplant drug is drawing significant interest across the industry.
The approval has been granted to Eugia Unit-I, with the product launch expected in the first quarter of FY27.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Best Crypto Presale 2026: Pepeto Surges Past $7.391M as Bitcoin ETFs Snap Five Week Outflow Streak and IPO Genie and Mutuum Finance Trail Behind
- ?Imperial war: on the war against Iran
- Full List of AI Companies That Bet Big On Super Bowl 60
- Ryanair issues warning to Irish passengers over new underseat bag size change
Source: Original →